AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 1.14 |
|---|---|
| Change | -0.040 3.509% |
| 52 W H/L (in USD) | 5.195/0.980 |
| EBITDA (in USD) | -215.146M |
| PE Ratio | -- |
| Volume | 2826168 |
| Diluted Eps TTM | -1.71 |
| Total Assets (in USD) | 229.181M |
|---|---|
| Total Liabilities (in USD) | 51.713M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 200.641M |
| Market Cap (in USD) | 209.996 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Invivyd Inc.
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Employees: 94
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. David Hering M.B.A. | CEO & Director | 1975 |
| 2. | Ms. Jill Andersen J.D. | Chief Legal Officer & Corp. Sec. | 1973 |
| 3. | Ms. Laura Walker Ph.D. | Co-Founder & Chief Scientific Officer | 1985 |
| 4. | Mr. Frederick W. Driscoll | Interim CFO, Principal Financial Officer & Principal Accounting Officer | 1951 |
| 5. | Dr. Rebecca Dabora Ph.D. | Chief Technology & Manufacturing Officer | 1959 |
| 6. | Kyra Rosow Faircloth | VP of Gov. Affairs, Advocacy & Corp. Communication | NA |
| 7. | Dr. Peter C. Schmidt M.D., M.Sc. | Chief Medical Officer | NA |
| 8. | Mr. David Hering M.B.A. | CEO & Director | 1976 |
| 9. | Ms. Jill Andersen J.D. | Chief Legal Officer & Corporate Secretary | 1973 |
| 10. | Mr. William E. Duke Jr., M.B.A. | Chief Financial Officer | 1972 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|
| Income Before Tax | -241.317M | -226.79M | - |
| Minority Interest | - | - | - |
| Net Income | -234.603M | -234.289M | - |
| Selling General Administrative | 47.044M | 36.517M | - |
| Gross Profit | - | - | - |
| Reconciled Depreciation | 0.462M | 0.001M | - |
| Ebit | -248.031M | -226.908M | -43.203M |
| Ebitda | -204.485M | -211.908M | - |
| Depreciation And Amortization | 43.546M | 15M | - |
| Operating Income | -248.031M | -226.908M | - |
| Other Operating Expenses | 226.258M | 219.408M | - |
| Interest Expense | 43.084M | 14.999M | - |
| Tax Provision | - | - | - |
| Interest Income | - | - | - |
| Net Interest Income | - | - | - |
| Income Tax Expense | -6.714M | 7.499M | - |
| Total Revenue | 0M | 0M | - |
| Total Operating Expenses | 226.258M | 219.408M | - |
| Cost Of Revenue | - | - | - |
| Total Other Income Expense Net | 6.714M | 0.118M | - |
| Net Income From Continuing Ops | -241.317M | -226.79M | - |
| Net Income Applicable To Common Shares | -241.317M | -226.79M | -111.975M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|
| Total Assets | 229.181M | 383.167M | 620.091M | 117.382M |
| Intangible Assets | - | - | - | - |
| Other Current Assets | 23.307M | 4.926M | 25.293M | 0.141M |
| Total Liab | 51.713M | 27.197M | 62.072M | 182.631M |
| Total Stockholder Equity | 177.468M | 355.97M | 558.019M | -65.249M |
| Other Current Liab | 40.895M | 21.955M | 56.277M | 4.919M |
| Common Stock | 0.011M | 0.011M | 0.011M | 0.001M |
| Capital Stock | 0.011M | 0.011M | 0.011M | 89.707M |
| Retained Earnings | -732.069M | -533.426M | -292.109M | -65.319M |
| Good Will | - | - | - | - |
| Other Assets | - | 0.191M | 3.297M | - |
| Cash | 200.641M | 92.076M | 542.224M | 114.988M |
| Cash And Equivalents | - | - | - | - |
| Total Current Liabilities | 50.291M | 25.031M | 62.06M | 13.072M |
| Current Deferred Revenue | - | - | - | - |
| Net Debt | -198.476M | -88.352M | -542.224M | -114.988M |
| Short Term Debt | 1.443M | 1.559M | - | - |
| Short Long Term Debt | - | - | - | - |
| Short Long Term Debt Total | 2.165M | 3.724M | - | - |
| Other Stockholder Equity | 680.358M | 506.49M | 850.125M | -89.637M |
| Property Plant Equipment | - | 2.282M | 0.083M | - |
| Total Current Assets | 224.881M | 376.917M | 616.711M | 117.382M |
| Long Term Investments | - | - | - | - |
| Short Term Investments | 0M | 279.915M | 49.194M | - |
| Net Receivables | 0.933M | 0.377M | 0.229M | - |
| Long Term Debt | - | - | - | - |
| Inventory | - | -0.377M | - | - |
| Accounts Payable | 7.953M | 1.517M | 5.783M | 8.153M |
| Accumulated Other Comprehensive Income | -0.013M | -0.272M | -0.008M | - |
| Non Currrent Assets Other | 0.175M | 0.191M | 3.297M | - |
| Non Current Assets Total | 4.3M | 6.25M | 3.38M | 0M |
| Capital Lease Obligations | 2.165M | 3.724M | - | - |
| Long Term Debt Total | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|
| Investments | -228.962M | -50.627M | -50.627M |
| Total Cashflows From Investing Activities | -230.667M | -50.711M | -50.711M |
| Total Cash From Financing Activities | 0.506M | 662.683M | 222.101M |
| Net Income | -241.317M | -226.79M | -111.975M |
| Change In Cash | -450.148M | 427.236M | 197.122M |
| Begin Period Cash Flow | 542.224M | 114.988M | - |
| End Period Cash Flow | 92.076M | 542.224M | 114.988M |
| Total Cash From Operating Activities | -219.987M | -184.736M | -24.979M |
| Depreciation | 0.462M | 0.001M | 0.001M |
| Other Cashflows From Investing Activities | - | - | - |
| Dividends Paid | - | - | - |
| Change To Inventory | - | - | - |
| Sale Purchase Of Stock | -0.004M | 0M | - |
| Other Cashflows From Financing Activities | 0.269M | 331.778M | -3.385M |
| Capital Expenditures | 1.705M | 0.084M | 0.084M |
| Change In Working Capital | -16.13M | 22.793M | - |
| Other Non Cash Items | 15.35M | 0.066M | - |
| Free Cash Flow | -221.692M | -184.82M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Growth Compy Commingled Pl O | 2 years ago | 4801817 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 2986726 |
| 3. | Fidelity Growth Company Fund | 2 years ago | 2585815 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 797404 |
| 5. | Fidelity Growth Company K6 | 2 years ago | 699256 |
| 6. | Fidelity Extended Market Index | 2 years ago | 318871 |
| 7. | Fidelity Series Growth Company | 2 years ago | 318317 |
| 8. | Schwab US Small-Cap ETF™ | 2 years ago | 256791 |
| 9. | Bridgeway Ultra-Small Company | 2 years ago | 211800 |
| 10. | BlackRock Extended Equity Market K | 2 years ago | 132186 |
| 11. | Bridgeway Ultra-Small Company Market | 2 years ago | 100000 |
| 12. | iShares Micro-Cap ETF | 2 years ago | 99111 |
| 13. | BlackRock Extended Mkt Composite | 2 years ago | 95441 |
| 14. | Avantis US Small Cap Equity ETF | 2 years ago | 92385 |
| 15. | Fidelity Total Market Index | 2 years ago | 91078 |
| 16. | Fidelity Series Total Market Index | 2 years ago | 73962 |
| 17. | Fidelity Nasdaq Composite Index | 2 years ago | 65809 |
| 18. | Vanguard Balanced Index Inv | 2 years ago | 58006 |
| 19. | Northern Trust Extended Eq Market Idx | 2 years ago | 50405 |
| 20. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 50405 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Maverick Capital Ltd | 2 years ago | 11765787 |
| 2. | Deep Track Capital, LP | 2 years ago | 10953937 |
| 3. | M28 Capital Management LP | 2 years ago | 9248250 |
| 4. | FMR Inc | 2 years ago | 8411969 |
| 5. | Alphabet Inc | 2 years ago | 4527122 |
| 6. | Slate Path Capital LP | 2 years ago | 3735000 |
| 7. | 683 Capital Management LLC | 2 years ago | 3475000 |
| 8. | Orbimed Advisors, LLC | 2 years ago | 2690300 |
| 9. | Vanguard Group Inc | 2 years ago | 2611202 |
| 10. | Bain Capital Life Sciences Investors, LLC | 2 years ago | 1799595 |
| 11. | Millennium Management LLC | 2 years ago | 1523342 |
| 12. | Redmile Group, LLC | 2 years ago | 1440725 |
| 13. | Gilder Gagnon Howe & CO LLC | 2 years ago | 1249111 |
| 14. | BlackRock Inc | 2 years ago | 899980 |
| 15. | Marshall Wace Asset Management Ltd | 2 years ago | 754907 |
| 16. | Geode Capital Management, LLC | 2 years ago | 581090 |
| 17. | Susquehanna International Group, LLP | 2 years ago | 515326 |
| 18. | Jacobs Levy Equity Management, Inc. | 2 years ago | 435338 |
| 19. | Bridgeway Capital Management, LLC | 2 years ago | 325300 |
| 20. | Charles Schwab Investment Management Inc | 2 years ago | 311254 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...